High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases

INTRODUCTION: Hormone receptor (HR)-positive metastatic breast cancer (MBC) is usually treated with hormone therapy. In postmenopausal females, aromatase inhibitors (AIs) are usually used as first-line therapy, and fulvestrant is used subsequently. The optimal treatment beyond fulvestrant has not be...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Ryutaro, Nagao, Yasuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: June, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086043/
https://www.ncbi.nlm.nih.gov/pubmed/25028579
http://dx.doi.org/10.1159/000363649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086043/
https://www.ncbi.nlm.nih.gov/pubmed/25028579
http://dx.doi.org/10.1159/000363649

Ejemplares similares